Aidan Synnott

Oncodesign Services has appointed Aidan Synnott as CEO

Oncodesign Services has announced the appointment of Aidan Synnott as its new Chief Executive Officer (CEO).

Synnott has more than two decades of experience in biomedical research, as well as extensive knowledge in global contract research organisation operations and management.

He most recently served as Corporate Vice President of Global Discovery Services at Charles River Laboratories, where he spent 16 years.

During his time at Charles River, Synnott held operational and business development roles, notably managing operations across the company’s discovery and safety assessment and research models portfolio.

In his latest position, Synnott will aim to bring together Oncodesign’s capabilities into a unified offering. He will be based in France and will oversee the company’s operations across sites in Dijon, Paris and Leiden, the Netherlands.

Synnott said he will focus on “aligning [Oncodesign’s] structure and mindset with the priorities of today’s drug discovery teams”.

Werner Lanthaler, former CEO of Evotec and newly appointment Chairman of Oncodesign’s Board, added: “With Aidan’s client-first mindset and track record in global discovery operations, Oncodesign Services is well-positioned to expand its impact.”